Daewoong Pharmaceutical announced that its smart patient monitoring system, thynC (Think Better, Sync Smarter), is the first domestically developed digital health device in Korea to receive insurance reimbursement approval. At a press conference in Seoul, the company outlined its vision for a more efficient and cost-effective medical checkup system through digital healthcare advancements.
Co-developed with Seers Technology, thynC is a remote monitoring system integrating wearable biosensors, a management app, and AI algorithms. It tracks key vital signs such as ECG, body temperature, and oxygen saturation, providing real-time insights for medical staff to monitor patients remotely.
Cho Byung-ha, head of Daewoong’s marketing division, emphasized the growing role of digital healthcare and AI-driven disease prediction in improving patient care. The company plans to expand thynC’s use across multiple medical departments, enhancing inpatient monitoring efficiency.
One of thynC’s key benefits is reducing the need for frequent in-person patient checks, making remote monitoring ideal for non-face-to-face care, especially during crises like the COVID-19 pandemic. Lee Young-shin, CEO of Seers Technology, highlighted its ability to detect critical conditions such as cardiac arrest, sepsis, and falls, ensuring immediate intervention. Given Korea’s shortage of medical residents and nurses, thynC aims to improve hospital efficiency and patient care quality.
Click here to read the original news story.